This is a Phase II study of the combination of All-Trans Retinonic Acid (ATRA) and PD-1 inhibition (Retifanlimab) in patient with recurrent IDH-mutant glioma. …

GliomaIDH MutationAstrocytoma+1 more

~Estimated

~$10 – $8,750

Stephen Bagley, MD, MSCENCT05345002

Phase 1

Early Phase 1 Window of Opportunity Study of Oral DSP-0390 in Gliomas

This study focuses on determining the pharmacokinetic and pharmacodynamic effect of DSP-0390 in brain and blood from patients with IDH-mutant glioma undergoing…

Glioma, MalignantIDH Mutation

~Estimated

~$10 – $6,250

Washington University School of MedicineNCT06636162